Kornimate/medical-research-clean huggingface dataset:
digital media usage with impulsivity and attention deficit in children

Conditions: Attention-Deficit-Disordered Children

Summary: to explore the relationship between children's digital media usage and attention, activity, parenting pressure; to explore the relationship between family basic data factors and screen usage.

background: digital products are inseparable from life. parents may feel that teaching materials are educational because of their high availability.meaning, busy work, helping to share care or short respite, etc., and providing digital products for children, it is very important to understand children's behavior, usage habits, and the relationship between parents.according to the american academy of pediatrics, parents should limit their exposure to most types of screen time until the child is 2 years old , and children 2-5 years old should be less than one hour per day, and it is recommended to watch high quality program content, accompanied by adults. the standards for screen time in various countries generally follow this policy.however, many studies have found that most children spend far more screen time than recommended guidelines. research in canada and the united states indicates that children aged three to five spend more than two hours a day on average. according to a tracking study, children aged three to five were surveyed on their in terms of screen use, it was found that compared with children who watched less than half an hour, children who used more than two hours a day had more significant implicit and explicit behavioral problems, namely withdrawal, nervousness, anxiety, irritability and attention deficit, and restless behavior. objective: to explore the relationship between children's digital media usage and attention, activity, parenting pressure; to explore the relationship between family basic data factors and screen usage. methods: individual caregivers were interviewed through paper or electronic questionnaires to assess children's and families' digital media usage habits, children's activity levels, and parental stress. the following assessment tools were used. including digital media use survey at home (refer to surveillance of digital-media habits in early childhood questionnaire, smallq™), chinese version of parental child activity scale (werry-weiss peters activity scale chinese version, wwpas), parental stress scale brief form (parenting stress index: short form, psi/sf)

Eligibility criteria:
inclusion criteria: * caregivers whose children are currently receiving early treatment and who can cooperate with the questionnaire; * the child's family has the habit of using digital media devices; * the child's main complaints include inattention and impulsivity; * the child's age is 3 to 6 years old. exclusion criteria: * the child has other specific diagnosed diseases, such as autism group, sensory disorder, known genetic and genetic diseases, etc.
aerobic exercise for cognitive functioning in patients with substance use disorder

Conditions: Substance Abuse; Cognitive Dysfunction

Summary: impaired cognitive function is common among patients with substance use disorder (sud). this is particularly related to executive functions (ef), which includes abilities like decision-making, consequence analysis and impulse/self-control. ef is recognized as an important determinant of treatment outcome as it is associated with dropout rate, attendance to therapy sessions and absence of relapse following treatment termination. exercise seem to improve cognitive/executive functions, particularly in individuals with cognitive impairments. aerobic exercise also affects signaling substances and growth factors known to inhibit neural degeneration, and improves cerebral insulin sensitivity and blood flow, contributing to improved brain function. there is a lack of knowledge regarding how to improve ef in sud patients, and whether such improvements can benefit other parts of the treatment, such as psychotherapy. aerobic exercise is a well-recognized and cost-effective intervention for cardiovascular and metabolic health, with promising effects on cognitive/executive functions. a randomized controlled trial will be carried out to investigate the effects of aerobic exercise on ef, molecular markers of neuroplasticity and brain function, and treatment outcome in sud patients. the investigators expect to achieve new knowledge regarding cognitive impairment among sud patients and to what extent aerobic exercise can improve cognitive abilities and treatment outcome.


Eligibility criteria:
inclusion criteria: * diagnosed substance use disorder (sud) by icd-10 * being in residential inpatient treatment for sud at lade addiction treatment center exclusion criteria: * recent participation in regular aerobic high-intensity interval training (hiit) * admissions shorter than 12 weeks * pregnant * history of brain injury (except concussions) * any acute or chronic somatic or psychiatric condition (e.g. heart disease or psychosis) or a medication that would limit the ability to participate in the exercise training and testing procedures, or any of the other assessments.

Keywords: exercise therapy high-intensity interval training
post prandial high resolution impedance- manometry

Conditions: Gastro-esophageal Reflux

Summary: nine to 30% of the population suffers from gastro-esophageal reflux disease (gerd) - suggestive symptoms (heartburn, regurgitation, chest pain, chronic couch, sore throat). proton pump inhibitor (ppi) is usually the first line treatment. however 20 to 60% of patients have persistent symptoms on proton pump inhibitor. complementary examinations are then required to determine the cause of persistent symptoms (non compliance to treatment, persistent esophageal acid exposure despite proton pump inhibitor, non acid reflux, reflux hypersensitivity, functional symptoms, rumination syndrome...). the gold standard to detect reflux episodes in patients on proton pump inhibitor therapy is 24-h ambulatory esophageal ph-impedance monitoring. esophageal high resolution impedance-manometry might help to determine gastro-esophageal reflux disease mechanisms especially when performed post prandially. further some publications demonstrated that the number of reflux episodes detected during the post prandial period might be well correlated to the total number of reflux episodes recorded during 24 h. the hypothesis of this study is that 1-hour post prandial esophageal high resolution impedance-manometry might be useful to diagnose gastro-esophageal reflux disease and can replace in some instances 24-h esophageal ph-impedance monitoring. therefore the aim is to compare the number of reflux episodes detected with esophageal high resolution impedance-manometry performed during 1-h post prandial period to the total number of reflux episodes detected during 24-h ambulatory esophageal ph-impedance monitoring.


Eligibility criteria:
inclusion criteria: * patient of both gender older than 18 years * patient referred for post prandial esophageal high resolution manometry combined with impedance and ambulatory 24-h ph-impedance monitoring on proton pump inhibitor * heartburn and/or regurgitation despite double dose proton pump inhibitor therapy * proven gastro-esophageal reflux disease off proton pump inhibitor (los angeles grade b, c or d esophagitis and/or esophageal acid exposure \> 5% on esophageal ph monitoring off proton pump inhibitor) * absence of major esophageal motility disorders (achalasia, esophago-gastric junction outflow obstruction, esophageal spasm, jackhammer esophagus, absent contractions) * patient who does not decline to participate to the study exclusion criteria: * patient younger than 18 years * pregnancy or breast feeding * previous history of esophago-gastric surgery ( including anti-reflux surgery, heller myotomy, bariatric surgery) * patient with severe renal insufficiency * patient with severe cardiac insufficiency * patient legally incompetent or unable to give consent * patient who declines to participate to the study * participation to another study at the same time
soft tissue thickness on submerged and non submerged implants

Conditions: Tooth Loss; Edentulousness

Summary: changes in the marginal bone level surrounding the implant are the frequently used parameters in assessing the short- and long-term success. multiple biological and biomechanical factors have been reported to adversely affect marginal bone level. recently, initial vertical mucosal tissue thickness has also been reported to have an impact on bone stability.the hypothesis of present study is that soft tissue thickness on implant placement has no positive impact of crestal bone remodeling.

the aim of this study is to evaluate the clinical and radiographical results of submerged and nonsubmerged implants with thin (\ 3 mm) soft tissue over 1.5 year after implant placement. all submerged and nonsubmerged implants were randomly placed as split-mouth. clinical periodontal parameters were recorded. crestal bone levels were analyzed from the day of implants inserted to 1.5 year after prosthetic loading on digitally standardized radiographs. non-parametric test were used for statistically analysis.

Eligibility criteria:
inclusion criteria: * being older than 18 years of age * generally healthy patients, no medical contraindication for implant surgery * missing teeth in upper jaw posterior and more than one tooth in neighbourhood area * no bone augmentation procedures before and during implant placement. exclusion criteria: * poor oral hygiene * history of periodontitis * smoking * diabetes * alcoholism * taking medication which interferes soft and hard tissue healing * bruxism.

Keywords: soft tissue thickness dental implant crestal bone loss
salbutamol, pharmacogenetics and breathing mechanics

Conditions: Bronchoconstriction; Inhaled Salbutamol; Cycling Performance

Summary: athletes using asthma medications called β2-agonists win a disproportionately high number of medals at olympic games. due to a large variety in the genes that affect how individuals respond to β2-agonists, the investigators will look at variations in the genetic response to these medications by dividing athletes into high-responders and low-responders. the investigators will then compare athletic performance after the inhalation of β2-agonists to placebo. furthermore, the investigators will analyze the effect of β2-agonists on breathing mechanics. due to differences in their anatomy females may decrease the energy needed for breathing during high-intensity exercise to a greater extent compared to male athletes after the inhalation of β2-agonists.


Eligibility criteria:
inclusion criteria: * trained, experienced cyclists * maximal oxygen consumption of at least 50ml/kg/min or 4l/min for women; and 60ml/kg/min or 5l/min for men * athletes with and without exercise-induced bronchoconstriction exclusion criteria: * any uncontrolled heart or lung condition * maximal oxygen consumption of less than 50ml/kg/min or 4l/min for women; and less than 60ml/kg/min or 5l/min for men * pregnancy * smoking

Keywords: exercise-induced bronchoconstriction (eib) inhaled salbutamol performance enhancing cycling
effects of roaccutane on ca, p, pth and vitamin d metabolites in the treatment of sever acne

Conditions: Acne

Summary: serum levels ca, p, pth and vitamin d metabolites before and after treatment with isotretinoin for sever acne

few studies has been done of serum levels ca, p, pth and vitamin d metabolites in patients receiving isotretinoin .in this study we measured serum levels ca, p, pth and vitamin d metabolites before and after treatment with isotretinoin for sever acne in 30 patients . the patients had no kown skeletal, endocrine ,renal and gastrointestinal disorders.

Eligibility criteria:
inclusion criteria: * sever acne exclusion criteria: * renal disorders * gastrointestinal disorders * skeletal disorders * endocrine disorders * drugs such as glucocorticoids , thiazide diuretics, mineral multivitamins, anti acids, tetracyclines

Keywords: acne isotretinoin calcium. vitamin d
continuous glucose monitor use in pregnancy

Conditions: Type 2 Diabetes Treated With Insulin; Pregnancy, High Risk

Summary: the purpose of this study is to perform a randomized controlled trial among 180 pregnant women with type 2 diabetes mellitus (t2dm) comparing continuous glucose monitor (cgm) use to the standard of care of multiple daily fingerstick glucose monitoring and its impact on large for gestational age infants, maternal glycemic control, patient satisfaction, and additional adverse perinatal outcomes.

a continuous glucose monitor (cgm) can provide detailed insight into daily glucose fluctuations and individual glucose patterns, and it is advised for patients with type 1 diabetes mellitus and advanced type 2 diabetes mellitus (t2dm). despite this recommendation, pregnant women are not receiving the same standard of care. it has been studied minimally in pregnant women with t2dm, despite preliminary studies showing improvement in adverse perinatal outcomes and glycemic control among pregnant women with type 1 diabetes. therefore, there is a paucity of data regarding cgm use among pregnant women with t2dm, and significant potential to reduce the significant multigenerational effects associated with diabetes in pregnancy with this technology. the study team therefore propose to perform a randomized controlled trial among 180 pregnant women with t2dm comparing cgm use to the standard of care of multiple daily fingerstick glucose monitoring and its impact on large for gestational age infants, maternal glycemic control, patient satisfaction, and additional adverse perinatal outcomes.

Eligibility criteria:
inclusion criteria: women will be deemed eligible for the study by the following inclusion criteria: * 1) age greater than or equal to 18 years old * 2) singleton gestation less than or equal to 14 weeks at initial obstetric visit * 3) established diagnosis of t2dm by laboratory criteria including hemoglobin a1c ≥6.5%, oral glucose tolerance test ≥200 mg/dl, or fasting plasma glucose ≥126 mg/dl * 4) receiving prenatal care at umass memorial health care (ummhc) and plans to deliver at ummhc * 5) able and willing to provide informed consent exclusion criteria: women will be deemed ineligible for the study based on the following exclusion criteria: * 1) known diagnosis of type 1 diabetes or gestational diabetes * 2) plan to receive prenatal care or delivery outside of ummhc * 3) inability to provide informed consent * 4) multifetal gestation

Keywords: type 2 diabetes pregnancy
model for heart failure exacerbation reduction trial

Conditions: Acute on Chronic Heart Failure

Summary: heart failure is the leading cause of hospitalizations and readmissions in the united states and is a tremendous economic strain on our healthcare system. there is currently, based on national averages, a 30% readmission rate and 10% mortality rate within 3 months of being hospitalized for heart failure. retrospective studies have shown benefit to using biomarkers such as bnp to guide inpatient heart failure management. our own ccf retrospective study showed that decreasing nt-probnp by 23%, making patients fluid negative by more than 1.3l, and discharging patients with serum sodium above 135 reduces readmission rates significantly. the purpose of this study is to prospectively use the above mentioned goals in the treatment of heart failure in order to reduce heart failure readmission and mortality rates.

all hf patients admitted to ccf will receive a short consent form. the study will enroll patients for one year. physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the 3 (above mentioned) criteria are met. physicians will receive a copy of consent forms, educational bulletins, and discharge forms (as described in the physician education document which is attached to this application). log-rank test will be used to compare groups. chi-square will be used to compare prospective patients with retrospective controls (obtained in 2010).

Eligibility criteria:
inclusion criteria: * must have either acute on chronic heart failure or chronic heart failure regardless of presenting/primary complaint to fulfill chf dx, must have 2+ of the following: * clinical: dyspnea, orthopnea, pnd, edema, s3, rales, improve w diuretics * radiographic: pulm venous congestion, pleural effs, cardiomegaly * lab: nt pro bnp \> 1000 exclusion criteria: * none
inors - international observational registry on schizophrenia with injectable risperidone and oral antipsychotics

Conditions: Schizophrenia

Summary: international observational registry on schizophrenia

this is an observational, non-interventional registry designed to assess medication usage patterns and to explore, in clinical routine practice, long-term outcomes and relevant factors for patient adherence to treatment, in patients receiving antipsychotic treatment with risperidone long-acting injectable (rlai) or oral antipsychotics. six month retrospective data and 1 year prospective data will be collected. according to label

Eligibility criteria:
inclusion criteria: * patients must satisfy the following criteria to be eligible for documentation in this non-interventional study: diagnosis of schizophrenia as well as 6 months of retrospective clinical records * newly initiated on or switched to rlai or an oral antipsychotic treatment (either atypical or conventional), not longer than 2 weeks ago * signed informed consent (either signed by the patient or his/her legal representative) is available at the beginning of documentation * any schizophrenic patient (including those for whom a legal representative must sign consent) can be involved in the study exclusion criteria: * established treatment refractory schizophrenia, defined as treatment failures with adequate trials (adequate as judged by the treating physician) of more than 2 second generation (atypical) antipsychotics and/or clozapine * history of neuroleptic malignant syndrome

Keywords: risperdal consta
exploratory study of single-port robot-assisted gastrectomy

Conditions: Gastric Cancer

Summary: this clinical study was a prospective, single-center, single-arm exploratory study. subjects who meet the inclusion criteria will be enrolled in this study, where surgeons will perform single-port robot-assisted gastrectomy, and explore and evaluate the safety and efficacy of this clinical application.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years old and age ≤80 years old, regardless of gender; 2. patients who met the surgical indications and were confirmed by the investigator to be in need of laparoscopic surgery. 3. patients with american society of anesthesiologists (asa) physical status classification ⅰ-ⅲ. 4. be able to cooperate with the completion of visits and related examinations specified in the protocol. 5. subjects voluntarily participated in the clinical trial and agreed or their guardians agreed to sign an informed consent. exclusion criteria: 1. patients with severe heart, lung, brain, liver, or kidney diseases can not tolerate surgery or anesthesia; 2. those who cannot tolerate pneumoperitoneum; 3. patients with serious systemic diseases that are not suitable for surgical treatment according to the judgment of the investigator; 4. patients with a history of severe bleeding disease, hematopoietic dysfunction or coagulation dysfunction, who are not suitable for surgical treatment according to the judgment of the investigator, and long-term use of anticoagulant and antiplatelet drugs (antiplatelet aggregation drugs were discontinued less than 1 week before surgery); 5. patients with active pulmonary tuberculosis; 6. hiv antibody positive; hepatitis b surface antigen (hbsag) positive and hepatitis b virus dna (hbv-dna) copy number higher than the detection limit or normal range; hepatitis c virus (hcv) antibody positive; patients with positive treponema pallidum antibody and high risk of infection judged by the researcher; 7. with epilepsy, psychiatric history or cognitive impairment; 8. pregnant and lactating women; 9. extensive and severe adhesion in the abdominal cavity caused the inability to perform puncture to establish pneumoperitoneum, and it was difficult to isolate and expose the lesion; a history of major abdominal surgery and abdominal radiotherapy were included, according to the investigator\&#39;s judgment situations where there is a risk of extensive adhesion; 10. participants who participated in other interventional clinical trials within 3 months before screening; 11. other circumstances that the investigator deemed inappropriate to participate in the trial.
copeptin: disease severity indicator

Conditions: Lower Respiratory Tract and Lung Infections; Ventilator Lung; Bronchopneumonia; Bronchitis

Summary: copeptin serves as a biomarker emanating from the pituitary gland, functioning as the precursor to arginine vasopressin (avp). its role in the regulation of endothelial dysfunction, inflammation, and water-electrolyte balance has been established. the measurement of avp levels poses challenges due to its brief half-life and the intricate nature of its detection method. in contrast, copeptin provides an indirect means of gauging circulating avp levels, as it can be conveniently assessed through a sandwich immunoassay. as a neuroendocrine stress hormone, copeptin emerges as a prognostic indicator, reflective of an individual's stress burden. moreover, its applicability extends to various acute conditions such as ischemic stroke or myocardial infarction. notably, copeptin proves to be a dependable tool in the differential diagnosis of diverse ailments characterized by polyuria and polydipsia. lower respiratory tract infection (lrti) stands as the predominant cause of morbidity and mortality among children and adolescents globally. notably, copeptin has demonstrated utility in forecasting the severity and complications associated with severe pneumonia in adults. while early investigations into copeptin's role in pediatric lrti suggest its potential for diagnosing pneumonia and predicting complications, the outcomes of these studies present conflicting results. although there has been a notable increase in studies on copeptin in pediatric patients over the past decade, research specifically exploring its correlation with pneumonia remains scarce. this prospective case-control study is designed to investigate the potential association between copeptin levels and the severity of illness in pediatric patients with pneumonia. the study aims to determine whether copeptin levels can serve as a reliable predictor of disease severity in pneumonia, offering valuable insights for clinical application. the outcomes of this research may contribute significantly to our comprehension of copeptin's role in disease prognosis and management, thereby facilitating the development of more efficacious diagnostic and therapeutic approaches. additionally, the study seeks to identify the factors influencing copeptin levels and establish a cut-off value for copeptin in pediatric patients diagnosed with pneumonia.


Eligibility criteria:
inclusion criteria: * being diagnosed with pneumonia, * the family must have given informed consent for the study. exclusion criteria: * individuals with underlying lung conditions (such as cystic fibrosis, bronchopulmonary dysplasia, asthma, bronchiectasis, tuberculosis), * individuals with underlying chronic illnesses (inclusive of heart, kidney, liver, gastrointestinal, and endocrine disorders), * individuals with obesity or malnutrition, * individuals with hyponatremia detected in their tests, * individuals with signs of dehydration, * individuals with a history of hospitalization within the last 72 hours.